Free Trial
NASDAQ:MRNA

Moderna (MRNA) Stock Price, News & Analysis

$133.27
-4.63 (-3.36%)
(As of 06/18/2024 ET)
Today's Range
$131.52
$137.27
50-Day Range
$101.41
$166.61
52-Week Range
$62.55
$170.47
Volume
3.97 million shs
Average Volume
4.19 million shs
Market Capitalization
$51.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$129.02

Moderna MarketRank™ Stock Analysis

Analyst Rating
Hold
2.24 Rating Score
Upside/​Downside
3.2% Downside
$129.02 Price Target
Short Interest
Healthy
5.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.71
Upright™ Environmental Score
News Sentiment
0.47mentions of Moderna in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$57.38 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.46) to ($5.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.65 out of 5 stars

Medical Sector

242nd out of 913 stocks

Biological Products, Except Diagnostic Industry

28th out of 152 stocks

MRNA stock logo

About Moderna Stock (NASDAQ:MRNA)

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

MRNA Stock Price History

MRNA Stock News Headlines

mobile phone screen with logo lettering of moderna pharma, stock market chart background
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. NASDAQ: MNRA made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA (mRNA) technology for the development of innovative treatments.
mobile phone screen with logo lettering of moderna pharma, stock market chart background
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA
[Urgent] Protect your money before November
Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.
[Urgent] Protect your money before November
Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.
Moment Of Truth Approaches For Moderna's RSV Vaccine
Moderna (NASDAQ:MRNA) Shares Down 2.2% on Insider Selling
7 Struggling Stocks to Sell Before July 2024
3 Reasons to Buy Moderna Stock
See More Headlines
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/02/2024
Today
6/18/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:MRNA
Fax
N/A
Employees
5,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$129.02
High Stock Price Target
$231.00
Low Stock Price Target
$60.00
Potential Upside/Downside
-3.2%
Consensus Rating
Hold
Rating Score (0-4)
2.24
Research Coverage
17 Analysts

Profitability

Net Income
$-4,714,000,000.00
Net Margins
-115.82%
Pretax Margin
-93.19%

Debt

Sales & Book Value

Annual Sales
$6.85 billion
Book Value
$36.33 per share

Miscellaneous

Free Float
324,988,000
Market Cap
$51.07 billion
Optionable
Optionable
Beta
1.54

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Moderna, Inc.:

  • Moderna's mRNA technology has shown great potential in developing vaccines for infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases, which could lead to significant revenue growth.
  • Recent insider transactions indicate confidence in the company's future, with the president acquiring a substantial number of shares, signaling positive sentiment.
  • Hedge funds have been increasing their positions in Moderna, with notable firms like Cetera Advisors LLC and Cetera Investment Advisers significantly raising their stakes, reflecting institutional confidence.
  • Moderna's institutional ownership percentage is high at 68.33%, indicating strong support from institutional investors who often conduct in-depth research before investing.
  • Despite recent challenges, Moderna's stock price has shown resilience, and with a record date price of $105.95, there is potential for capital appreciation.

Cons

Investors should be bearish about investing in Moderna, Inc. for these reasons:

  • Moderna's stock has experienced a significant decline of 48.24% in the past fifty-two weeks, indicating volatility and potential risks associated with investing in the company.
  • The short percentage of float is relatively high at 6.96%, suggesting that there is a notable amount of short interest in Moderna's stock, which could lead to increased price volatility.
  • While the mRNA technology holds promise, there is still uncertainty surrounding its long-term effectiveness and market acceptance, which could impact the company's future growth prospects.
  • The month-to-month change percentage in shares shorted has been negative at 4.63%, indicating that there may be bearish sentiment among some investors regarding Moderna's future performance.
  • With a relatively low average daily volume of 5,170,000 shares traded, there may be liquidity challenges for investors looking to buy or sell large quantities of Moderna's stock.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, June 3, 2024. Please send any questions or comments about these Moderna pros and cons to contact@marketbeat.com.

MRNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Moderna stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 2 sell ratings, 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings
or view top-rated stocks.

What is Moderna's stock price target for 2024?

17 Wall Street analysts have issued 12 month target prices for Moderna's shares. Their MRNA share price targets range from $60.00 to $231.00. On average, they anticipate the company's stock price to reach $129.02 in the next year. This suggests that the stock has a possible downside of 3.2%.
View analysts price targets for MRNA
or view top-rated stocks among Wall Street analysts.

How have MRNA shares performed in 2024?

Moderna's stock was trading at $99.45 at the start of the year. Since then, MRNA stock has increased by 34.0% and is now trading at $133.27.
View the best growth stocks for 2024 here
.

When is Moderna's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our MRNA earnings forecast
.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) posted its earnings results on Thursday, May, 2nd. The company reported ($3.07) EPS for the quarter, beating the consensus estimate of ($3.59) by $0.52. The company earned $167 million during the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 115.82% and a negative trailing twelve-month return on equity of 20.10%. Moderna's revenue was down 91.0% compared to the same quarter last year. During the same period last year, the firm posted $0.19 EPS.

What guidance has Moderna issued on next quarter's earnings?

Moderna updated its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $3.9 billion.

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

Moderna (MRNA) raised $499 million in an IPO on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Who are Moderna's major shareholders?

Moderna's stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.66%), Vanguard Group Inc. (10.19%), Capital World Investors (0.95%), Bank of New York Mellon Corp (0.60%), Mawer Investment Management Ltd. (0.50%) and Bellevue Group AG (0.45%). Insiders that own company stock include Arpa Garay, David W Meline, James M Mock, Juan Andres, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge and Tal Zvi Zaks.
View institutional ownership trends
.

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNA) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners